Noxopharm (ASX: NOX) has reported positive preclinical pharmacokinetic data for its SOF-SKN drug candidate, demonstrating a significant skin half-life of approximately 3.5 days with minimal systemic absorption.
The study in normal and disease-like skin examined the uptake of SOF-16, the active component of SOF-SKN, at the highest dose used in the HERACLES trial.
The results show that SOF-16 remained in the skin for an extended period, marking a key step towards refining its dosing regimen and preparing for future regulatory submissions.
Drug concentration in the dermis was consistent across both normal and disease-like skin models.
The drug was almost entirely localised to the epidermis and dermis layers, which are the intended active layers for treatment.
Importantly, absorption into the bloodstream was below quantifiable levels at all time points, suggesting a highly localised action.
Dosing and Regulatory Preparation
These preclinical results are crucial for the next stages of SOF-SKN development.
The data are intended to help define an appropriate human dosing frequency, which could potentially be less frequent than a daily application given the prolonged skin retention.
The company plans to include these results in the regulatory submission package required for the next development stage of the drug candidate.
Noxopharm is also engaging a Contract Research Organisation (CRO) to support preparations for a human trial.
Recent Executive Changes
In other recent developments, Noxopharm announced a key leadership transition.
Dr Olivier Laczka was appointed Chief Executive Officer, effective April 15, 2026.
This followed the resignation of previous CEO and Managing Director, Dr Gisela Mautner.
Dr Laczka previously served as the Chief Scientific Officer for Inflammation and was a key driver behind the strategic development of the Sofr technology platform, aligning with the company’s focus.
Financial Context and Outlook
Noxopharm continues to manage its financial position amidst ongoing research and development efforts.
The company reported a widening half-year loss for the period ending December 31, 2025, driven by these R&D and other operating costs.
Net assets deteriorated to a deficiency, primarily due to continued cash burn and increased convertible note and derivative liabilities.
To support its funding, Noxopharm entered into an At-the-Market (ATM) facility post-period on February 27, 2026, providing access to up to $5 million in standby equity over an extended period.
Additionally, the company received a $2,806,583 rebate from the Australian Government R&D Tax Incentive scheme for FY2024-25, which strengthened its cash position.
Balanced Perspective
Noxopharm’s SOF-SKN preclinical data presents a promising profile for sustained skin retention and minimal systemic exposure, potentially enabling less frequent dosing and supporting future regulatory filings.
However, the company continues to navigate financial pressures, including cash burn and liabilities, alongside a recent leadership transition, which remain key considerations for investors.